Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

This study is testing whether chemotherapy given after surgery can reduce the chance of uterine leiomyosarcoma returning in patients identified as "high-risk" by a special biological tumor test. Uterine leiomyosarcoma is a rare and aggressive type of uterine cancer, and identifying who is most likely to benefit from additional treatment is a key challenge. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with uterine leiomyosarcoma confirmed by a specialist pathologist - Your surgery (total hysterectomy) was performed within the past 8 weeks and removed all visible cancer (stage I, complete resection) - You have not had chemotherapy before for this cancer - Your tumor tissue is available for a specialized biological risk test (CINSARC NanoCind®) - Your heart, blood, liver, and kidney function meet the required thresholds **You may NOT be eligible if...** - You have another type of uterine sarcoma (e.g., adenosarcoma or endometrial sarcoma) - You have evidence of remaining or measurable disease after surgery - You have had another cancer in the past 5 years (some treated cancers may be acceptable) - You have planned pelvic radiation after surgery - You have heart problems, active hepatitis B or C, or HIV - You are breastfeeding Talk to your doctor to see if this trial is right for you.